Linked Life Data

18463961

Source:http://linkedlifedata.com/resource/pubmed/id/18463961

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-5-8
pubmed:abstractText
Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1341-9625
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
156-60
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
pubmed:affiliation
Institute of Oncology, Istanbul University, Onkoloji Enstitusu, Capa, 34390, Istanbul, Turkey. faruktas2002@yahoo.com
pubmed:publicationType
Journal Article